Altium Capital Management LLC Makes New $2.86 Million Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Altium Capital Management LLC acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 95,000 shares of the biopharmaceutical company's stock, valued at approximately $2,860,000. Altium Capital Management LLC owned 0.06% of TG Therapeutics at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Quadrant Capital Group LLC lifted its stake in shares of TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after purchasing an additional 975 shares during the period. Blue Trust Inc. lifted its position in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares during the period. Smartleaf Asset Management LLC boosted its stake in TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 1,737 shares during the period. Finally, Synergy Asset Management LLC bought a new position in shares of TG Therapeutics during the fourth quarter valued at approximately $75,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Stock Performance

TGTX stock traded up $1.62 on Wednesday, hitting $39.61. The company had a trading volume of 896,902 shares, compared to its average volume of 3,093,139. The stock has a market cap of $6.22 billion, a price-to-earnings ratio of -396.06 and a beta of 2.14. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock's 50-day simple moving average is $36.61 and its 200 day simple moving average is $32.13. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $43.32.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. The company had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, equities research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TGTX has been the topic of a number of analyst reports. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.